Anthony Perissinotti
@ajperissinotti
Followers
725
Following
6K
Statuses
739
RT @sanamloghavi: My takeaways from our @HemeReports Menin session #leusm 1. Despite promising results of Menin-i (in a very tough to tre…
0
21
0
RT @zucenka: Rough number of good points made in this episode about Blin(k)atumomab: 182! But the best one: we spend billions on drugs that…
0
3
0
RT @WolverHeme: Step inside from the polar vortex 🥶, grab a drink ☕️🥂, and listen to our latest episode - "Navigating a BlinatumoMAD World"…
0
3
0
RT @KFHemeOnc: For those who cheered too soon - an excellent analysis of the greatly misinterpreted and spurious 'OS benefit', especially w…
0
2
0
RT @WolverHeme: Check out our latest episode "The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma" with…
0
4
0
RT @WolverHeme: Just in time for the holidays! 🥂🎄 "Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates" #lymsm @aj…
0
3
0
RT @SuyogCancer: We do clinical trials .You don't do it. So we know more than you and you should not criticise us . Just clap 👏 and shut…
0
3
0
RT @HadidiSamer: #ASH24 #mmsm Few important observations on AQUILA This is in top of prior observations I shared 🧵
0
24
0
RT @AaronGoodman33: I have done this poll many times. This is the highest amount who have stated they will treat smoldering myeloma with D…
0
6
0
RT @Eddie_Cliff: Postprogression treatment is critical to the interpretation of overall survival data 👇🏻 #ASH24
0
3
0
RT @rajshekharucms: AQUILA Trial is out! Important to note that ~30% of patients received a clearly suboptimal 1st line anti-myeloma treatm…
0
7
0
RT @RahulBanerjeeMD: #ASH24 this is the only time where I don't say #downwithdex... In this case, #downwithtoci and prescribe "pocket dex"…
0
5
0
RT @YungGonzaga: When I see something like this, where the title says one thing and the data something completely different, I’m reminded o…
0
3
0
RT @NEJM: Original Article: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children (AALL1731)
0
22
0
RT @thisisJamesD: How do you treat low grade CRS due to myeloma bispecifics? We investigated differences of using dexamethasone and toci in…
0
11
0
RT @JohnPLeonardMD: We have several scenarios in chronic #lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a P…
0
17
0
RT @TalhaBadarMD: #ASH24 Dr. Zeidan @Dr_AmerZeidan presented KOMET-07 data with high response rate 100% and >80% with triplet combos in NPM…
0
11
0
RT @ALL_Hub_: CONGRESS #ASH24 | PRESENTATION Melissa A. Burns, @DanaFarber presented results from DFCI ALL Consortium Protocol 16-001. Only…
0
1
0
RT @audvin: Late to the party, but I see we have new entrant to the most BASED medical podcast title competition. "A Bunch of ASHholes Di…
0
1
0